Use of 2-methylene-19-nor-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat secondary hyperparathyroidism in patients previously treated with calcimimetics
AssigneeWisconsin Alumni Research Foundation
InventorsHector F. DeLuca, Lori A. Plum, Margaret Clagett-Dame
Life of this patent
Estimating the term…
Abstract
Disclosed are methods of administering 2-methylene-19-nor-(20S)-1α,25-dihydroxyvitamin D3 to treat and/or prevent secondary hyperparathyroidism and/or its accompanying symptoms in a subject having or at risk for developing secondary hyperparathyroidism, including a subject previously administered a calcimimetic.
Claims12
A method of treating secondary hyperparathyroidism or the symptoms thereof in a subject having secondary hyperparathyroidism or at risk for developing secondary hyperparathyroidism, wherein the subject previously was administered a calcimimetic to treat the secondary hyperparathyroidism, the method comprising administering a therapeutically effective amount of 2-methylene-19-nor-(20S)-1α,25-dihydroxyvitamin D3 or a pharmaceutically acceptable salt thereof to the subject wherein secondary hyperparathyroidism or the symptoms thereof are treated.
Dependencies are inferred from the claim text.